NCT03113110View on ClinicalTrials.gov

Empagliflozin in Post-Transplantation Diabetes Mellitus

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 15, 2017

Primary Completion Date

June 13, 2017

Study Completion Date

May 31, 2018

Conditions
Posttransplant Diabetes Mellitus
Interventions
DRUG

Empagliflozin 10 mg

PTDM patients on previous antidiabetic treatment (\<40 IU insulin (in some cases plus oral antidiabetics)) receive Empagliflozin, ideally as monotherapy

Trial Locations (1)

1090

Department of Internal Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Austria, Vienna

All Listed Sponsors
lead

Medical University of Vienna

OTHER

NCT03113110 - Empagliflozin in Post-Transplantation Diabetes Mellitus | Biotech Hunter | Biotech Hunter